Eli Lilly's Taltz and Zepbound Deliver Promising Results
Game-Changing Results for Psoriatic Arthritis Surprising everyone this side of the stock ticker, Eli Lilly (NYSE: LLY) just announced their new data: pairing Taltz (ixekizumab) with Zepbound brought a clinical revolution for folks battling psoriatic arthritis and obesity. It's like finding gold under your mat—a combo punching PsA better than Taltz going solo. AT 52...
Continue Reading